GLUE vs SANA: stock comparison and AI forecast
Monte Rosa Therapeutics, Inc. (GLUE) and Sana Biotechnology, Inc. (SANA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
GLUE Monte Rosa Therapeutics, Inc.
- Market Cap
- $923M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
SANA Sana Biotechnology, Inc.
- Market Cap
- $730M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- GLUE is 1.3 times larger than SANA by market capitalization ($923M against $730M).
- SANA carries 1.79 times debt per unit of equity, against 0.42 times for GLUE.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | GLUE | SANA |
|---|---|---|
| Market Cap | $923M | $730M |
| P/B Ratio | 1.89x | 4.73x |
| EPS | $-1.76 | $-0.79 |
| Book Value/Share | $5.71 | $0.52 |
| Revenue/Share | $0.29 | – |
| FCF/Share | $-0.38 | $-0.45 |
Profitability & Margins
| Metric | GLUE | SANA |
|---|---|---|
| ROE | -33.1% | -137.0% |
| ROA | -23.3% | -49.1% |
| ROIC | -28.8% | -71.1% |
| Operating Margin | -741.8% | – |
| Net Margin | -657.2% | – |
| EBT Margin | -668.8% | – |
| Tax Rate | 1.7% | – |
Financial Health
| Metric | GLUE | SANA |
|---|---|---|
| Current Ratio | 10.58x | 1.38x |
| D/E Ratio | 0.42x | 1.79x |
| Financial Leverage | 1.42x | 2.79x |
| Working Capital | $572M | $47M |
Cash Flow
| Metric | GLUE | SANA |
|---|---|---|
| Operating Cash Flow | -$24M | -$132M |
| Free Cash Flow | -$32M | -$135M |
| Capital Spending | -$8M | -$3M |
| OCF Growth YoY | -186.8% | – |
| FCF Growth YoY | -234.5% | – |
| FCF/Sales | -130.8% | – |
| CapEx/Sales | 32.7% | – |
Operational Efficiency
| Metric | GLUE | SANA |
|---|---|---|
| Asset Turnover | 0.04x | – |
| Fixed Assets Turnover | 0.8x | – |
Income Statement
| Metric | GLUE | SANA |
|---|---|---|
| Total Revenue | $25M | – |
| Operating Income | -$182M | -$219M |
| Net Income | -$161M | -$212M |
| R&D Expense | $171M | $124M |
Dividend & Shareholder Information
| Metric | GLUE | SANA |
|---|---|---|
| Shares Outstanding | 85M | 299M |
| Net Income Growth | -766.6% | – |
| EPS Growth | -540.0% | – |
GLUE vs SANA: stock comparison and AI forecast
Which is bigger, GLUE or SANA?
GLUE is 1.3 times larger than SANA by market capitalization ($923M against $730M).
Which one does Intratio's AI model rank higher, GLUE or SANA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.